clinical development

ICON is a clinical research organisation providing outsourced clinical development and commercialisation services to the pharmaceutical, biotechnology and medical device industries. It offers clinical, consulting and commercial services across sectors including biotech, government and public health, medical devices and pharmaceuticals, and has contributed to over 60 FDA/EMA approved therapies in oncology CGT in the last 5 years.

analytical method development and validationclinical trialsformulation developmentglobal depot and distributionmedical imagingpackaging and labellingRegulatory Affairssmall-batch manufacturingstability testingtranslation and linguistic validation

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. Built on its proprietary ImmTAX platform, it develops bispecific therapies for cancer, infectious diseases, and autoimmune diseases, including multiple cancers, HIV and HBV.

biomanufacturingbispecific therapy developmentCMC developmentT cell receptor (TCR) therapy discovery and development

Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company that has pioneered an innovative platform technology focused on development and commercialization of a novel class of orally delivered polyclonal antibodies for enteric disease prevention and treatment. Founded and incorporated in Australia in 1994, it has been listed on the ASX since April 30, 1999 under the symbol IMC, and its ADSs and warrants are listed on NASDAQ under IMRN and IMRNW.

antibody engineeringdevelopment and commercialisation of polyclonal antibodiesmanufacturing process development

Programming B Cells to Deliver Novel Therapies for Patients How We’re Doing It Immusoft is the world leader in engineering B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our platform, called Immune System Programming (ISP™) entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into biofactories (known as plasma cells), each of which manufactures and secretes thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce personalized protein therapeutics. Once we have programmed the B cells, we then expand and differentiate into plasma cells that will then produce large amounts of our therapeutic protein. In the clinic, we then infuse the programmed cells back into the patient, where they take up.

B cell engineeringcell therapyplasma cell differentiationpreclinical research

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases. Its platform is based on a naturally occurring subset of NK cells deficient in the FceR1g protein, derived from healthy donors. The company is based in Houston, TX, and Seattle, WA.

cell therapy developmentG-NK cell expansion processmanufacturing science and technology

iOnctura is a clinical-stage biotechnology company developing precision medicines for cancer and other challenging diseases. Founded in 2017, it develops high impact, low disruption therapies targeting the tumor-stroma-immune interface, focusing on neglected and hard to treat cancers with more effective, less toxic treatments.

drug developmentoncology researchsmall molecule drug discovery

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a biopharmaceutical company dedicated to developing life-changing medicines for people with rare diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines including leading therapies addressing rare epilepsies, cancers and sleep disorders, and pursues research and development across a pipeline of innovative therapeutics. Corporate headquarters are in Dublin, Ireland, with offices in North America and Europe.

commercializationmanufacturingresearch and development

Kura Oncology, Inc. is a biopharmaceutical company that discovers and develops novel cancer therapeutics, aiming to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Its therapies are designed to selectively target cancer cells, and it investigates them in combination with standards of care. It focuses on areas including head and neck cancer, lung cancer and acute leukemias.

drug developmentdrug discoveryprecision oncology

Kuria Therapeutics is a pharmaceutical company developing a platform of novel NRF2 activators to treat blinding ophthalmic diseases. Its lead candidate, KTX-1161, is a preservative-free topical ophthalmic formulation of SCO-116, a small-molecule NRF2 activator, being advanced through IND-enabling development for Fuchs' endothelial corneal dystrophy.

drug developmentIND-enabling development